Cost-effectiveness analysis of treating patients with ntrk-positive cancer with the histology-independent therapy entrectinib (Value in Health, 2022)

(untitled) - Huygens, S; Vellekoop, H; Versteegh, M; Santi, I; Szilberhorn, L; Zelei, T; Nagy, B; Tsiachristas, A; Koleva-Kolarova, R; Wordsworth, S; Rutten-van Mölken, M